875781-45-6

Basic information

• Product Name: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine
• Synonyms: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine;2-bromo-7-iodo-5-(4-methylbenzenesulfonyl)-5H-pyrrolo[2,3-b]pyrazine;2-bromo-7-iodo-5-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyrazine
• CAS NO: 875781-45-6
• Molecular Formula: C₁₃H₉BrIN₃O₂S
• Molecular Weight: 478.11
• Product Categories: CHIRAL CHEMICALS
• Mol File: 875781-45-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 560.1 °C at 760 mmHg
• Flash Point: 292.6 °C
• Appearance: /
• Density: 2.11 g/cm³
• Vapor Pressure: 1.41E-12mmHg at 25°C
• Refractive Index: 1.777
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine(875781-45-6)
• EPA Substance Registry System: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine(875781-45-6)

Safety Data

• Hazardous Substances Data: 875781-45-6(Hazardous Substances Data)

Usage

General Description

2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine is a chemical compound with the molecular formula C9H6BrIN2O2S. It is a heterocyclic compound that contains a pyrrolopyrazine core with bromine, iodine, and tosyl groups attached. 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine is used in organic synthesis and pharmaceutical research, particularly in the development of novel drug molecules. Its unique structure and reactivity make it a valuable building block for the creation of diverse chemical structures and potential drug candidates. In addition, the presence of halogen atoms in the molecule can also impart important properties such as increased lipophilicity and bioactivity, making it a potentially valuable tool in drug discovery and development.

InChI:InChI=1/C13H9BrIN3O2S/c1-8-2-4-9(5-3-8)21(19,20)18-7-10(15)12-13(18)16-6-11(14)17-12/h2-7H,1H3

Upstream product

• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 
• 875781-42-3 N-(5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-yl)acetamide 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 875781-44-5 2-bromo-7-iodo-5H-pyrrolo[3,2-b]pyrazine 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 875781-46-7 2-bromo-7-(2-methoxy-phenyl)-5-(toluene-4-sulfonyl)-5h-pyrrolo[2,3-b]pyrazine 
• 1229583-75-8 2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine 
• 1229582-37-9 7-(1H-indol-5-yl)-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[3,2-b]pyrazine 

Relevant articles and documents

TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a tricyclic compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES

Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

MLK INHIBITORS AND METHODS OF USE

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.